Deucravacitinib vs Placebo and Apremilast in Moderate to Severe Plaque Psoriasis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of the American Academy of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
J Am Acad Dermatol 2022 Jul 09;[EPub Ahead of Print], AW Armstrong, M Gooderham, RB Warren, KA Papp, B Strober, D Thaçi, A Morita, JC Szepietowski, S Imafuku, E Colston, J Throup, S Kundu, S Schoenfeld, M Linaberry, S Banerjee, A BlauveltFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.